Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20955841 | 0.81 | MCL1 (0.43) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL15022943 | 0.72 | NPC1 (0.54) | NPC1RAB9AALDH1A1KMT2AHTT | |
| SCHEMBL507614 | 0.72 | KMT2A (0.66) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL9001814 | 0.71 | LMNA (0.66) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| Hydrochloric Acid SCHEMBL4451181 | 0.71 | RAB9A (0.38) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| 4-Methylbenzoic Acid SCHEMBL28992508 | 0.70 | ALDH1A1 (0.81) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL245428 | 0.69 | ALDH1A1 (0.59) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL12139834 | 0.69 | ALDH1A1 (0.59) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL11250713 | 0.69 | ALDH1A1 (0.58) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL6057098 | 0.68 | SCN1A (0.69) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2610248-B1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND | TEIJIN PHARMA LTD (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-8916714-B2 | Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using palladium compound | TEIJIN PHARMA LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| EP-2610248-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND | Teijin Pharma Limited (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130158272-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND | TEIJIN PHARMA LIMITED (JP) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158272-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND | XDH, AOC1, PAH | NPC1 1248/4885RAB9A 3425/4885SMN1; SMN2 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.